Daratumumab

Background: Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.

Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.

Indication: Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.

Associated Conditions: Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Phase 2

Active, not recruiting

Interventions: Drug: Dexamethasone
Drug: Cyclophosphamide
Biological: Daratumumab
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Phase 2

Completed

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.